ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
The programme has already drawn over 120 complex percutaneous coronary intervention (PCI) case submissions from across the country
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
The conclave brought together over 1,000 delegates from across India and internationally
The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.
Subscribe To Our Newsletter & Stay Updated